| Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study JR Perry, K Bélanger, WP Mason, D Fulton, P Kavan, J Easaw, C Shields, ... Journal of clinical oncology 28 (12), 2051-2057, 2010 | 444 | 2010 |
| The RECITE study: a Canadian prospective, multicenter study of the incidence and severity of residual neuromuscular blockade LP Fortier, D McKeen, K Turner, É de Médicis, B Warriner, PM Jones, ... Anesthesia & Analgesia 121 (2), 366-372, 2015 | 277 | 2015 |
| Haemonchus contortus: selection at a glutamate-gated chloride channel gene in ivermectin-and moxidectin-selected strains WJ Blackhall, JF Pouliot, RK Prichard, RN Beech Experimental parasitology 90 (1), 42-48, 1998 | 242 | 1998 |
| Reversal of P-glycoprotein-associated multidrug resistance by ivermectin JF Pouliot, F L'Heureux, Z Liu, RK Prichard, E Georges Biochemical pharmacology 53 (1), 17-25, 1997 | 217 | 1997 |
| Isoform I (mdr3) is the major form of P-glycoprotein expressed in mouse brain capillaries. Evidence for cross-reactivity of antibody C219 with an unrelated protein L Jette, JF Pouliot, GF Murphy, R Beliveau Biochemical Journal 305 (3), 761-766, 1995 | 59 | 1995 |
| A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma MG Smylie, R Wong, C Mihalcioiu, C Lee, JF Pouliot Investigational new drugs 25, 155-159, 2007 | 55 | 2007 |
| Cemiplimab plus chemotherapy versus chemotherapy alone in advanced NSCLC: 2-year follow-up from the phase 3 EMPOWER-lung 3 part 2 trial T Makharadze, M Gogishvili, T Melkadze, A Baramidze, D Giorgadze, ... Journal of Thoracic Oncology 18 (6), 755-768, 2023 | 47 | 2023 |
| Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously … ME Trudeau, MJ Clemons, L Provencher, L Panasci, L Yelle, D Rayson, ... Journal of Clinical Oncology 27 (35), 5906-5910, 2009 | 47 | 2009 |
| Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study P Power, G Stuart, A Oza, D Provencher, JR Bentley, WH Miller Jr, ... Gynecologic Oncology 114 (3), 410-414, 2009 | 43 | 2009 |
| P-glycoprotein of blood brain barrier: cross-reactivity of Mab C219 with a 190 kDa protein in bovine and rat isolated brain capillaries E Beaulieu, M Demeule, JF Pouliot, DA Averill-Bates, GF Murphy, ... Biochimica et Biophysica Acta (BBA)-Biomembranes 1233 (1), 27-32, 1995 | 42 | 1995 |
| The Temozolomide RESCUE study: a Phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent … JR Perry, WP Mason, K Belanger, P Kavan, D Fulton, J Easaw, S Kirby, ... Journal of Clinical Oncology 26 (15_suppl), 2010-2010, 2008 | 32 | 2008 |
| Palmitoylation of the glucose transporter in blood-brain barrier capillaries JF Pouliot, R Béliveau Biochimica et Biophysica Acta (BBA)-Biomembranes 1234 (2), 191-196, 1995 | 32 | 1995 |
| First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1 … M Özgüroğlu, S Kilickap, A Sezer, M Gümüş, I Bondarenko, M Gogishvili, ... The Lancet Oncology 24 (9), 989-1001, 2023 | 30 | 2023 |
| A phase II study of temozolomide therapy for poor-risk patients aged⩾ 60 years with acute myeloid leukemia: low levels of MGMT predict for response JM Brandwein, L Yang, AD Schimmer, AC Schuh, V Gupta, RA Wells, ... Leukemia 21 (4), 821-824, 2007 | 28 | 2007 |
| Methods for using macrocyclic lactone compounds as multidrug resistance reversing agents in tumor and other cells RK Prichard, JF Pouliot, E Georges US Patent 6,114,376, 2000 | 27 | 2000 |
| Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high‐risk myelodysplastic syndrome patients pre‐screened for low O6‐methylguanine DNA … JM Brandwein, J Kassis, B Leber, D Hogge, K Howson‐Jan, MD Minden, ... British journal of haematology 167 (5), 664-670, 2014 | 20 | 2014 |
| Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer NB Leighl, GD Goss, PG Lopez, RL Burkes, JE Dancey, YH Rahim, ... Lung cancer 52 (3), 327-332, 2006 | 20 | 2006 |
| BIBW22 BS, potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells. Z Liu, F Lheureux, JF Pouliot, A Heckel, U Bamberger, E Georges Molecular pharmacology 50 (3), 482-492, 1996 | 17 | 1996 |
| Health management program: factors influencing completion of therapy with high-dose interferon alfa-2b for high-risk melanoma N Levesque, K Mitchinson, D Lawrie, L Fedorak, D Macdonald, ... Current Oncology 15 (1), 36, 2008 | 12 | 2008 |
| Machine learning models for identifying predictors of clinical outcomes with first-line immune checkpoint inhibitor therapy in advanced non-small cell lung cancer Y Li, M Brendel, N Wu, W Ge, H Zhang, P Rietschel, RGW Quek, ... Scientific Reports 12 (1), 17670, 2022 | 11 | 2022 |